These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 6689305)
21. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092 [TBL] [Abstract][Full Text] [Related]
22. Adverse effects related to thionamide drugs and their dose regimen. Werner MC; Romaldini JH; Bromberg N; Werner RS; Farah CS Am J Med Sci; 1989 Apr; 297(4):216-9. PubMed ID: 2523194 [TBL] [Abstract][Full Text] [Related]
23. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Tajiri J; Noguchi S; Murakami T; Murakami N Arch Intern Med; 1990 Mar; 150(3):621-4. PubMed ID: 2310281 [TBL] [Abstract][Full Text] [Related]
24. Lactose intolerance following antithyroid drug medications. Petrini L; Usai P; Caradonna A; Cabula R; Mariotti S J Endocrinol Invest; 1997 Oct; 20(9):569-70. PubMed ID: 9413813 [TBL] [Abstract][Full Text] [Related]
25. Antithyroid drugs. Cooper DS N Engl J Med; 1984 Nov; 311(21):1353-62. PubMed ID: 6387489 [TBL] [Abstract][Full Text] [Related]
26. In vitro immunoreactivity to propylthiouracil, methimazole, and carbimazole in patients with Graves' disease: a possible cause of antithyroid drug-induced agranulocytosis. Wall JR; Fang SL; Kuroki T; Ingbar SH; Braverman LE J Clin Endocrinol Metab; 1984 May; 58(5):868-72. PubMed ID: 6200492 [TBL] [Abstract][Full Text] [Related]
27. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. Otsuka F; Noh JY; Chino T; Shimizu T; Mukasa K; Ito K; Ito K; Taniyama M Clin Endocrinol (Oxf); 2012 Aug; 77(2):310-5. PubMed ID: 22332800 [TBL] [Abstract][Full Text] [Related]
28. Antithyroid drug treatment for graves' disease in children: a long-term retrospective study at a single institution. Ohye H; Minagawa A; Noh JY; Mukasa K; Kunii Y; Watanabe N; Matsumoto M; Suzuki M; Yoshihara A; Ito K; Ito K Thyroid; 2014 Feb; 24(2):200-7. PubMed ID: 23926918 [TBL] [Abstract][Full Text] [Related]
29. TSH receptor antibody measurements and prediction of remission in Graves' disease patients treated with minimum maintenance doses of antithyroid drugs. Okamoto Y; Tanigawa S; Ishikawa K; Hamada N Endocr J; 2006 Aug; 53(4):467-72. PubMed ID: 16820704 [TBL] [Abstract][Full Text] [Related]
30. Hepatotoxicity from antithyroid drugs. Vitug AC; Goldman JM Horm Res; 1985; 21(4):229-34. PubMed ID: 4007783 [TBL] [Abstract][Full Text] [Related]
31. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome. Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520 [TBL] [Abstract][Full Text] [Related]
32. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves' disease. Kashiwai T; Hidaka Y; Takano T; Tatsumi KI; Izumi Y; Shimaoka Y; Tada H; Takeoka K; Amino N Endocr J; 2003 Feb; 50(1):45-9. PubMed ID: 12733708 [TBL] [Abstract][Full Text] [Related]
33. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eisenstein Z; Weiss M; Katz Y; Bank H Eur J Pediatr; 1992 Aug; 151(8):558-9. PubMed ID: 1505570 [TBL] [Abstract][Full Text] [Related]
34. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period]. Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311 [TBL] [Abstract][Full Text] [Related]
36. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Takata K; Kubota S; Fukata S; Kudo T; Nishihara E; Ito M; Amino N; Miyauchi A Thyroid; 2009 Jun; 19(6):559-63. PubMed ID: 19445623 [TBL] [Abstract][Full Text] [Related]
37. The onset of antineutrophil cytoplasmic antibody-associated vasculitis immediately after methimazole was switched to propylthiouracil in a woman with Graves' disease who wished to become pregnant. Kimura M; Seki T; Ozawa H; Ishihara T; Komatsu M; Tajiri S; Yanagi H; Nishina M; Noh JY; Fukagawa M; Takagi A Endocr J; 2013; 60(3):383-8. PubMed ID: 23154533 [TBL] [Abstract][Full Text] [Related]
39. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342 [TBL] [Abstract][Full Text] [Related]